AU Stock MarketDetailed Quotes
ALA Arovella Therapeutics Ltd
- 0.195
- +0.005+2.63%
20min DelayClosing Auction Session Oct 17 14:55 AET
205.11MMarket Cap-21666P/E (Static)
0.205High0.187Low1.50MVolume0.190Open0.190Pre Close291.04KTurnover0.20552wk High0.20%Turnover Ratio1.05BShares0.07552wk Low-0.009EPS TTM147.84MFloat Cap360.698Historical HighLossP/E (Static)758.13MShs Float0.020Historical Low-0.009EPS LYR9.47%Amplitude--Dividend TTM17.73P/B1Lot Size--Div YieldTTM
About Arovella Therapeutics Ltd Company
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Company Profile
SymbolALA
Company NameArovella Therapeutics Ltd
Founded1999
MarketASX
Employees14
Fiscal Year Ends06-30
Address84 Hotham Street Corporate One
CityPreston
CountryAustralia
Zip Code3072
Phone+61 398636472
Websitehttps://www.arovella.com
Share RegistryAUTOMIC REGISTRY SERVICES
477 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000
1300 288 664
Company Executives
- Name
- Position
- Salary
- Michael Baker
- Chief Executive Officer and Managing Director
- --
- Thomas (Tom) Duthy
- Non-Executive Chairman
- --
- Gary Phillips
- Non-Executive Director
- --
- Elizabeth Stoner
- Non-Executive Director
- --
- Debora Barton
- Non-Executive Director
- --
- David Simmonds
- Non-Executive Director
- --
- Phillip Hains
- Company Secretary
- --
Analysis
Price Target
No Data
Heat List
AU
Overall
Symbol
Latest Price
% Chg
No Data